U.S. stock markets have been exceedingly volatile in 2022. This turbulent environment hasn't kept some of the world's best investors on the sidelines, however.
The billionaire brothers Julian and Felix Baker -- co-owners of the biotechnology focused hedge fund Baker Bros. Advisors -- are a prime example. The fund's most recent 13F filings with the Securities and Exchange Commission show that the fund was extremely active from a buying standpoint in the second quarter of 2022.
Perhaps most interestingly, the Baker brothers bought large chunks of small-cap healthcare stocks Affimed (NASDAQ: AFMD) , Cerus Corporation (NASDAQ: CERS) , and Replimune Group (NASDAQ: REPL) in the most recent quarter. All three of these biotech stocks have fallen in a big way over the course of 2022.
For further details see:
Billionaires Are Scooping Up These 3 Beaten-Down Biotech Stocks